Mr. David F. Hale has been the Chairman of the company since June 2019. Previouesly, he served as the Chairman and a Director of Private Oncternal in 2018. Before joining Private Oncternal, he was the Chairman and the Chief Executive Officer of the company Hale Biopharma Ventures, LLC. He also served as the Chief Executive Officer and the President of CancerVax Corporation and was the Chairman of Micromet Inc. Prior to that, he served as the President, the Chief Operating Officer and later on as the Chief Executive Officer of Hybritech Inc. Prior to that, he served in various positions in many companies such as Gensia Inc, Viagene Inc, and Women First HealthCare Inc among others.

Mr. James B. Breitmeyer has been the President, Chief Executive Officer and a Director of the company since June 2019. Previously, he served as the President, Chief Executive Officer and a Director of Private Oncternal. Before joining Private Oncternal, he was the President of Bavarian Nordic Inc, an Executive Vice President of Bavarian Nordic A/S. Prior to that, he served in many positions at several companies including Zogenix Inc, Cadence Pharmaceuticals Inc, Applied Molecular Evolution Inc and Serono Laboratories Inc among others. Mr. Breitmeyer was also the founder, President and the Chief Executive Officer of the Harvard Clinical Research Institute.

Mr. Richard G. Vincent has been the Chief Financial Officer, Treasurer and the Secretary of the company since April 2017. Previously, he served as the Chief Financial Officer, Treasurer and the Secretary of Private Oncternal. Before joining Private Oncternal, he served at Sorrento Therapeutics as the Chief Financial Officer and Secretary. Prior to that, he served as an independent Chief Financial Officer for many companies including Avalyn Pharma (co-founder), Elevation Pharmaceuticals and Meritage Pharma. Earlier in his career, he also served as the Chief Financial Officer for Verus Pharmaceuticals, Women First Healthcare and held a number of positions at Deloitte & Touche LLP.

Dr. Rajesh Krishnan has been the Chief Technology Officer of the company since 2020. Previously, he served as Vice President, Process Development and Manufacturing Sciences at Dynavax Technologies Corporation, where he led process validation, manufacturing, analytical sciences, drug process development and technology transfer services for commercial and clinical development programs. Prior to this, Dr. Krishnan served in Gilead Sciences, Inc. as Head of Biologics Drug Substance Process Development. Till 2012, he served in Pfizer, Merck & Co. Inc. and Amgen Inc. with leadership roles in process development and technology transfer for clinical and commercial biologics programs.

Mr. Salim Yazji has been the Chief Medical Officer of the company since 2021. Previously, he he served as Chief Executive Officer at Ajuta Therapeutics. He also founded Elpida Therapeutics in January 2019. He has also served on the Board of Directors at Versatope Therapeutics since April 2019. From March 2018 to January 2019, he served as Chief Medical Officer at PMV Pharma, and from November 2016 to February 2018, he served as Executive Vice President and Chief Medical Officer at Calimmune.